John Sazy, MD
Orthopaedic Surgery · Arlington, TXNPI 1043222722
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $14,708 of the $15,826 with a category attached, or 92.9%. Depuy Synthes Products, Inc. accounts for 92.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $12,718 and has fallen 98.4% since, to $209 in 2025.
Across 45 payments — averaging $351.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Depuy Synthes Products, Inc.$15K
- Stryker$348
- Providence Medical Technology, Inc.$296
- Xtant Medical Inc$254
- VB Spine LLC$41
- Vertex$39
- plus $140 from 7 others
What the payments were for
- Royalty or licence$14,70893%
- Food & beverage$1,1187%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Depuy Synthes Products, Inc. | 5 | $14,708 |
| Stryker | 20 | $348 |
| Providence Medical Technology, Inc. | 7 | $296 |
| Xtant Medical Inc | 2 | $254 |
| VB Spine LLC | 1 | $41 |
| Vertex | 2 | $39 |
| Si-bone, Inc. | 2 | $25 |
| Electronic Waveform Lab, Inc. | 1 | $23 |
| Orthofix Medical, Inc. | 1 | $22 |
| Vericel Corporation | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Theragen, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,826 in reported general payments places this provider in the 75th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 206 | $8,224 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 130 | $2,975 |
| Gabapentin | 96 | $1,662 |
| Tramadol Hcl | 100 | $1,117 |
| Cyclobenzaprine Hcl | 33 | $796 |
| Methocarbamol | 19 | $525 |
| Pregabalin | 13 | $483 |
| Tizanidine Hcl | 25 | $403 |
| Meloxicam | 104 | $402 |
| Nabumetone | 14 | $183 |
| Baclofen | 18 | $177 |
| Hydroxychloroquine Sulfate | 27 | $95 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Arlington
- Stephen BurkhartSan Antonio$185.3M
- Kirby HittTemple$9.1M
- Robert GrahamAustin$6.3M
- Richard JonesDallas$6.3M
- Stefan KreuzerHouston$6.2M
- Michael WirthSan Antonio$4.5M
- Stephen IncavoHouston$4.3M
- Thomas EdwardsHouston$4.1M
- James BrodskyDallas$2.5M
- Robert SchmidtFort Worth$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.